Evidence map›Paper›PMID 27486201›Full record

ArticleThe oncologist2016

Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.

Letizia Gandolfi, Cinzia Pellegrini, Beatrice Casadei, Vittorio Stefoni, Alessandro Broccoli, Lorenzo Tonialini, Alice Morigi, Lisa Argnani, Pier Luigi Zinzani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Letizia GandolfiInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Cinzia PellegriniInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Beatrice CasadeiInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Vittorio StefoniInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Alessandro BroccoliInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Lorenzo TonialiniInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Alice MorigiInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Lisa ArgnaniInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Pier Luigi ZinzaniInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy pierluigi.zinzani@unibo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) with reported long-term response duration in clinical trials, but few data are available regarding its role in long-term outcomes in real life. PATIENTS AND

methodsA single-center observational study was conducted on patients treated with BV in daily clinical practice to evaluate the long-term effectiveness of BV in HL and sALCL patients and to check whether clinical trial results are confirmed in a real-life context.

resultsThe best response rate in the treated 53 patients (43 HL and 10 sALCL) was 69.8% (with 46.5% complete response [CR]) in HL and 100% (80% CR) for sALCL, respectively. With a median patient follow-up of 36.8 months, the estimated median duration of response was 31.5 months for HL and 17.8 for sALCL, respectively. At the latest available follow-up, 75% of patients were still in response, with 43% without any consolidation. Toxicity was primarily neurological and it was rarely so serious to require dose reduction or interruption. In addition, it always reversed completely after the end of treatment.

conclusionOur data showed that 51% of patients treated with BV can be regarded as "long-term responders." Among these cases, for all patients who underwent stem cell transplantation immediately after BV, the procedure was consolidative. For patients who have remained in continuous CR without any consolidation after therapy, BV can induce prolonged disease control. IMPLICATIONS FOR PRACTICE: Brentuximab vedotin (BV) has shown a high overall response rate in refractory/relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, with reported long-term response duration in clinical trials, whereas few data are available regarding its role in long-term outcomes in real life. The data reported in this study suggest that BV can induce the same results in daily clinical practice. The data showed that 51% of patients treated with BV can be regarded as "long-term responders." Among these cases, BV can induce prolonged disease control in patients who have remained in continuous complete response without any consolidation after the drug.

Indexed as

AdolescentAdultAgedAged, 80 and overBrentuximab VedotinFemaleHodgkin DiseaseHumansImmunoconjugatesLymphoma, Large-Cell, AnaplasticMaleMiddle AgedRecurrenceRetrospective StudiesYoung AdultBrentuximab VedotinImmunoconjugatesBrentuximab vedotinHodgkin lymphomaLong-term responseReal lifeSystemic anaplastic large cell lymphoma

Identifiers

PMID27486201
PMCPMC5153337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.